bordetella pertussis d420
Vaccineexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 17, 2022 (NCT05136599)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Bordetella pertussisImmunity, active
Bordetella pertussis immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05136599 | Phase 1 | Jan 17, 2022 | Centers for Disease Control and Prevention (CDC), Dalhousie University, Intravacc, National Institute of Allergy and Infectious Diseases (NIAID), Vanderbilt University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Centers for Disease Control and Prevention (CDC) | Government | 1 | 0 | 1 | 2022 |
| Dalhousie University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Intravacc | For profit | 1 | 0 | 1 | 2022 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2022 |
| Vanderbilt University | Academic/Hospital | 1 | 0 | 1 | 2022 |
5 organizations
Page 1 / 1